# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
ATH-1105 is an orally delivered, positive modulator of the neurotrophic HGF system that is currently in a Phase 1 clinical tria...
JMP Securities analyst Jason Butler downgrades Athira Pharma (NASDAQ:ATHA) from Market Outperform to Market Perform.
BTIG analyst Thomas Shrader downgrades Athira Pharma (NASDAQ:ATHA) from Buy to Neutral.
Athira Pharma stock falls as the company reports mixed results from its Phase 2/3 LIFT-AD clinical trial for Alzheimer's tr...